The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
For patients with stage III or IV Hodgkin lymphoma, brentuximab vedotin is associated with a survival advantage, according to a study published online July 13 in the New England Journal of Medicine.
Jul 14, 2022
0
1
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found ...
Jul 11, 2022
0
6
The addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiation therapy (RT) was shown to lengthen both disease control and survival relative to RT alone as first-line therapy following surgery on ...
Jun 28, 2022
0
36
Results from the NRG Oncology phase III clinical trial NRG GOG-0212 indicated that treating women who received complete clinical response (CCR) after first-line platinum-taxane therapy for advanced ovarian, peritoneal, or ...
Jun 28, 2022
0
24
For patients with AIDS-related lymphoma (ARL), hypoalbuminemia predicts inferior outcome, according to a study published online June 18 in Infectious Agents and Cancer.
Jun 24, 2022
0
66
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), ...
Jun 6, 2022
0
11
The addition of tislelizumab to chemotherapy improves progression-free survival (PFS) in recurrent/metastatic nasopharyngeal cancer (RM NPC), according to a study presented April 18 as part of the American Society for Clinical ...
Apr 22, 2022
0
16
Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. ...
Apr 12, 2022
0
6
A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher ...
Apr 11, 2022
0
11
